Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

The whole-genome landscape of medulloblastoma subtypes

Open access
Northcott, Paul A., Buchhalter, Ivo, Morrissy, A. Sorana, Hovestadt, Volker, Weischenfeldt, Joachim, Ehrenberger, Tobias, Gröbner, Susanne, Segura-Wang, Maia, Zichner, Thomas, Rudneva, Vasilisa A., Warnatz, Hans-Jörg, Sidiropoulos, Nikos, Phillips, Aaron H., Schumacher, Steven, Kleinheinz, Kortine, Waszak, Sebastian M., Erkek, Serap, Jones, David T. W., Worst, Barbara C., Kool, Marcel, Zapatka, Marc, Jäger, Natalie, Chavez, Lukas, Hutter, Barbara, Bieg, Matthias, Paramasivam, Nagarajan, Heinold, Michael, Gu, Zuguang, Ishaque, Naveed, Jäger-Schmidt, Christina, Imbusch, Charles D., Jugold, Alke, Hübschmann, Daniel, Risch, Thomas, Amstislavskiy, Vyacheslav, Gonzalez, Francisco German Rodriguez, Weber, Ursula D., Wolf, Stephan, Robinson, Giles W., Zhou, Xin, Wu, Gang, Finkelstein, David, Liu, Yanling, Cavalli, Florence M. G., Luu, Betty, Ramaswamy, Vijay, Wu, Xiaochong, Koster, Jan, Ryzhova, Marina, Cho, Yoon-Jae, Pomeroy, Scott L., Herold-Mende, Christel, Schuhmann, Martin, Ebinger, Martin, Liau, Linda M., Mora, Jaume, McLendon, Roger E., Jabado, Nada, Kumabe, Toshihiro, Chuah, Eric, Ma, Yussanne, Moore, Richard A., Mungall, Andrew J., Mungall, Karen L., Thiessen, Nina, Tse, Kane, Wong, Tina, Jones, Steven J. M., Witt, Olaf, Milde, Till, Von Deimling, Andreas, Capper, David, Korshunov, Andrey, Yaspo, Marie-Laure, Kriwacki, Richard, Gajjar, Amar, Zhang, Jinghui, Beroukhim, Rameen, Fraenkel, Ernest, Korbel, Jan O., Brors, Benedikt, Schlesner, Matthias, Eils, Roland, Marra, Marco A., Pfister, Stefan M., Taylor, Michael D., Lichter, Peter · 2017 · Nature

Abstract

Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature22973

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of MB genomic datasets. Graphical summary of genomic, epigenomic, and transcriptomic MB datasets analysed in the study. PowerPoint slide
Figure 1 Summary of MB genomic datasets. Graphical summary of genomic, epigenomic, and transcriptomic MB datasets analysed in the study. PowerPoint slideCC BY · PubMed Central
Figure 2 Driver genes and pathways altered in MB. a, Oncoprint summarizing recurrently altered genes according to MB subgroup (n = 390; WGS series only). b, Top, Venn diagram summarizing the subgroup overlap of recurrently mutated genes (≥3 affected cases). Bottom, incidence plot of recurrently mutated genes (≥3 affected cases) detected in the series (n = 356 genes; n = 491 samples). c, Graphical summary of the most frequently mutated genes (≥10 affected cases) and their subgroup distribution. d, Venn diagram summarizing the significantly mutated gene lists output from multiple significance algorithms. e, Results from d restricted to Cancer Gene Census (CGC) genes. PowerPoint slide
Figure 2 Driver genes and pathways altered in MB. a, Oncoprint summarizing recurrently altered genes according to MB subgroup (n = 390; WGS series only). b, Top, Venn diagram summarizing the subgroup overlap of recurrently mutated genes (≥3 affected cases). Bottom, incidence plot of recurrently mutated genes (≥3 affected cases) detected in the series (n = 356 genes; n = 491 samples). c, Graphical summary of the most frequently mutated genes (≥10 affected cases) and their subgroup distribution. d, Venn diagram summarizing the significantly mutated gene lists output from multiple significance algorithms. e, Results from d restricted to Cancer Gene Census (CGC) genes. PowerPoint slideCC BY · PubMed Central
Figure 3 Mutational landscape of Group 3 and Group 4. a, b, Oncoprint summaries of recurrently mutated genes, structural variants, overexpression and somatic copy number variants (CNVs) in Group 3 (n = 131) and Group 4 (n = 193) MB. LOH, loss of heterozygosity; NA, not available. c, Bar graph depicting the proportion of cases per subgroup for which at least one driver event could be assigned. The proportion of cases explained in previous NGS studies versus the current study is shown. d, Mutually exclusive (ME) mutations in Group 3 and Group 4. PowerPoint slide
Figure 3 Mutational landscape of Group 3 and Group 4. a, b, Oncoprint summaries of recurrently mutated genes, structural variants, overexpression and somatic copy number variants (CNVs) in Group 3 (n = 131) and Group 4 (n = 193) MB. LOH, loss of heterozygosity; NA, not available. c, Bar graph depicting the proportion of cases per subgroup for which at least one driver event could be assigned. The proportion of cases explained in previous NGS studies versus the current study is shown. d, Mutually exclusive (ME) mutations in Group 3 and Group 4. PowerPoint slideCC BY · PubMed Central
Figure 4 Molecular features of methylation subtypes. a, t-SNE plot depicting new methylation subtypes detected in Group 3 and Group 4 (n = 740 samples). b, Methylation subtypes proportionally summarized according to consensus Group 3 and Group 4 subgroup definitions. c, Oncoprint summaries of driver genetic events according to methylation subtype. PowerPoint slide
Figure 4 Molecular features of methylation subtypes. a, t-SNE plot depicting new methylation subtypes detected in Group 3 and Group 4 (n = 740 samples). b, Methylation subtypes proportionally summarized according to consensus Group 3 and Group 4 subgroup definitions. c, Oncoprint summaries of driver genetic events according to methylation subtype. PowerPoint slideCC BY · PubMed Central
Figure 5 Recurrent hotspot indels target KBTBD4. a, Gene-level summary of somatic SNVs and indels targeting KBTBD4 in MB. Mutations are independently summarized according to subgroup. b, Distribution of wild-type (WT) and mutant KBTBD4 cases in methylation subtypes. c, Homology model of the KBTBD4 Kelch domain, highlighting the positions affected by hotspot insertions (shown as spheres). PowerPoint slide
Figure 5 Recurrent hotspot indels target KBTBD4. a, Gene-level summary of somatic SNVs and indels targeting KBTBD4 in MB. Mutations are independently summarized according to subgroup. b, Distribution of wild-type (WT) and mutant KBTBD4 cases in methylation subtypes. c, Homology model of the KBTBD4 Kelch domain, highlighting the positions affected by hotspot insertions (shown as spheres). PowerPoint slideCC BY · PubMed Central
Figure 6 Enhancer hijacking activates PRDM6 in Group 4 MB. a, Summary of structural variants (SVs) targeting the SNCAIP locus in Group 4. b, Group 4 MB expression box plots of genes mapping proximal to SNCAIP-associated structural variants. NS, not significant. c, Summary of annotated chromatin interactions (Hi-C), TADs (brown bars), CTCF chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and CTCF binding orientation (red and blue arrowheads), as well as SNCAIP-associated structural variants, CTCF ChIP–seq peaks, Group 4-specific super-enhancers (SEs), H3K27ac ChIP–seq peaks, and RNA-seq data derived from a subset of Group 4 MBs, stratified according to underlying SNCAIP structural variant status. d, Proposed model depicting inferred molecular basis of SNCAIP/PRDM6-associated enhancer hijacking. PowerPoint slide
Figure 6 Enhancer hijacking activates PRDM6 in Group 4 MB. a, Summary of structural variants (SVs) targeting the SNCAIP locus in Group 4. b, Group 4 MB expression box plots of genes mapping proximal to SNCAIP-associated structural variants. NS, not significant. c, Summary of annotated chromatin interactions (Hi-C), TADs (brown bars), CTCF chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) and CTCF binding orientation (red and blue arrowheads), as well as SNCAIP-associated structural variants, CTCF ChIP–seq peaks, Group 4-specific super-enhancers (SEs), H3K27ac ChIP–seq peaks, and RNA-seq data derived from a subset of Group 4 MBs, stratified according to underlying SNCAIP structural variant status. d, Proposed model depicting inferred molecular basis of SNCAIP/PRDM6-associated enhancer hijacking. PowerPoint slideCC BY · PubMed Central
Extended Data Figure 1 Mutational signatures in MB. a, b, Exposure plot (a) and heatmap (b) summarizing mutation signatures contributing ≥5% of the overall mutation burden per sample are depicted. Asterisks in b indicate subgroup-enriched signatures. c, d, Box plots showing the subgroup specificity of signatures 18 (c) and 5 (d). e, Correlation of signatures 1 and 5 with patient age. f, Summary of total somatic mutation counts observed in the series. g, Bar plot summarizing distribution of mutation signatures in MBs with outlier mutation counts. h, Rainfall plots depicting somatic mutation burden in typical (top) and hypermutated (bottom) SHH MBs.
Extended Data Figure 1 Mutational signatures in MB. a, b, Exposure plot (a) and heatmap (b) summarizing mutation signatures contributing ≥5% of the overall mutation burden per sample are depicted. Asterisks in b indicate subgroup-enriched signatures. c, d, Box plots showing the subgroup specificity of signatures 18 (c) and 5 (d). e, Correlation of signatures 1 and 5 with patient age. f, Summary of total somatic mutation counts observed in the series. g, Bar plot summarizing distribution of mutation signatures in MBs with outlier mutation counts. h, Rainfall plots depicting somatic mutation burden in typical (top) and hypermutated (bottom) SHH MBs.CC BY · PubMed Central
Extended Data Figure 2 Genome-wide summary of somatic SNVs. a, Precision-recall curves for different binomial P value cut-offs. Minimal and maximal precision values are shown in colour, mean precision is shown as dotted line. P value cut-offs for 200 bp window sizes are indicated. b, Manhattan plot showing the −log10 test statistic of 200 bp genomic windows plotted against their respective chromosomal positions. Red line indicates the genome-wide significance threshold (P = 10−25). High-confidence regions are shown in red; regions representing probable false positives are shown in blue. c, Summary of TERT promoter mutations observed in the series.
Extended Data Figure 2 Genome-wide summary of somatic SNVs. a, Precision-recall curves for different binomial P value cut-offs. Minimal and maximal precision values are shown in colour, mean precision is shown as dotted line. P value cut-offs for 200 bp window sizes are indicated. b, Manhattan plot showing the −log10 test statistic of 200 bp genomic windows plotted against their respective chromosomal positions. Red line indicates the genome-wide significance threshold (P = 10−25). High-confidence regions are shown in red; regions representing probable false positives are shown in blue. c, Summary of TERT promoter mutations observed in the series.CC BY · PubMed Central
Extended Data Figure 3 Prevalent candidate driver mutations observed in MB. a, b, Gene-level summaries of SNVs/indels inferred to predominantly result in loss-of-function (LOF) (a) or gain-of-function (GOF) (b) of known and putative MB driver genes.
Extended Data Figure 3 Prevalent candidate driver mutations observed in MB. a, b, Gene-level summaries of SNVs/indels inferred to predominantly result in loss-of-function (LOF) (a) or gain-of-function (GOF) (b) of known and putative MB driver genes.CC BY · PubMed Central
Extended Data Figure 4 Summary of fusion gene transcripts detected by RNA-seq. a–c, Schematic summaries of high-confidence fusion transcripts targeting known or putative MB driver genes, organized according to MB subgroup.
Extended Data Figure 4 Summary of fusion gene transcripts detected by RNA-seq. a–c, Schematic summaries of high-confidence fusion transcripts targeting known or putative MB driver genes, organized according to MB subgroup.CC BY · PubMed Central
Extended Data Figure 5 Candidate driver genes and pathways in MB subgroups. a, b, Box plots summarizing allelic expression fractions (a) and estimated clonality (b) inferred for prominent MB driver gene mutations. c, GO and pathway summary of recurrently mutated genes in MB. GO and pathway categories are grouped according to functional theme and the proportion of cases affected by individual pathway alterations are plotted per subgroup and across the series. d, Network summary of recurrently mutated genes involved in histone lysine methylation (GO accession 0034968).
Extended Data Figure 5 Candidate driver genes and pathways in MB subgroups. a, b, Box plots summarizing allelic expression fractions (a) and estimated clonality (b) inferred for prominent MB driver gene mutations. c, GO and pathway summary of recurrently mutated genes in MB. GO and pathway categories are grouped according to functional theme and the proportion of cases affected by individual pathway alterations are plotted per subgroup and across the series. d, Network summary of recurrently mutated genes involved in histone lysine methylation (GO accession 0034968).CC BY · PubMed Central
Extended Data Figure 6 Mutational landscape of WNT and SHH MB. a, b, Oncoprint summaries of recurrently mutated genes and cytogenetic alterations in WNT (a; n = 36 samples) and SHH (b; n = 131 samples). c, Gene-level summary of WNT subgroup-enriched CSNK2B and EPHA7 mutations. d, Summary of SWI/SNF superfamily-type complex (GO accession 0070603) mutations observed in patients with WNT MB. e, Gene-level summary of somatic IDH1 R132C mutations detected in MB. f, Quantification of methylcytosine beta-values detected in IDH1-mutant versus wild-type SHH MBs. g, Unsupervised hierarchical clustering of SHH MB methylation data, confirming CIMP in IDH1-mutated SHH MBs. h, Summary of histone acetyltransferase complex (GO accession 0000123) mutations observed in patients with SHH MB.
Extended Data Figure 6 Mutational landscape of WNT and SHH MB. a, b, Oncoprint summaries of recurrently mutated genes and cytogenetic alterations in WNT (a; n = 36 samples) and SHH (b; n = 131 samples). c, Gene-level summary of WNT subgroup-enriched CSNK2B and EPHA7 mutations. d, Summary of SWI/SNF superfamily-type complex (GO accession 0070603) mutations observed in patients with WNT MB. e, Gene-level summary of somatic IDH1 R132C mutations detected in MB. f, Quantification of methylcytosine beta-values detected in IDH1-mutant versus wild-type SHH MBs. g, Unsupervised hierarchical clustering of SHH MB methylation data, confirming CIMP in IDH1-mutated SHH MBs. h, Summary of histone acetyltransferase complex (GO accession 0000123) mutations observed in patients with SHH MB.CC BY · PubMed Central
Extended Data Figure 7 Somatic copy-number alterations in MB. a, Copy-number heat maps for individual MB subgroups derived from WGS series. b, Genome-wide copy-number summary plots for the MB dataset shown in a. c, GISTIC plots summarizing significant CNVs according to MB subgroup.
Extended Data Figure 7 Somatic copy-number alterations in MB. a, Copy-number heat maps for individual MB subgroups derived from WGS series. b, Genome-wide copy-number summary plots for the MB dataset shown in a. c, GISTIC plots summarizing significant CNVs according to MB subgroup.CC BY · PubMed Central
Extended Data Figure 8 t-SNE analysis of Group 3 and Group 4 methylation data. a, t-SNE plot of DNA methylation array data for 1,256 analysed MBs. b, t-SNE analysis of iteratively down-sampled Group 3 and Group 4 methylation data. c, Genome-wide copy-number summary plots for Group 3/Group 4 methylation subtypes. d, t-SNE plots showing the relative, normalized expression intensities of GFI1, GFI1B, MYC, MYCN and PRDM6 in methylation subtypes (n = 219). e, Expression heat map showing transcriptional diversity among new MB subtypes (n = 248).
Extended Data Figure 8 t-SNE analysis of Group 3 and Group 4 methylation data. a, t-SNE plot of DNA methylation array data for 1,256 analysed MBs. b, t-SNE analysis of iteratively down-sampled Group 3 and Group 4 methylation data. c, Genome-wide copy-number summary plots for Group 3/Group 4 methylation subtypes. d, t-SNE plots showing the relative, normalized expression intensities of GFI1, GFI1B, MYC, MYCN and PRDM6 in methylation subtypes (n = 219). e, Expression heat map showing transcriptional diversity among new MB subtypes (n = 248).CC BY · PubMed Central
Extended Data Figure 9 SNCAIP-associated enhancer hijacking in Group 4 MB. a, Quantile–quantile plot depicting the statistical inference of CESAM applied to systematically identify loci targeted by enhancer hijacking in Group 3 and Group 4 (n = 164) MB. b, Ascending PRDM6 expression in Group 4 MB annotated according to SNCAIP structural variant status.
Extended Data Figure 9 SNCAIP-associated enhancer hijacking in Group 4 MB. a, Quantile–quantile plot depicting the statistical inference of CESAM applied to systematically identify loci targeted by enhancer hijacking in Group 3 and Group 4 (n = 164) MB. b, Ascending PRDM6 expression in Group 4 MB annotated according to SNCAIP structural variant status.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 1,112

Metadata

Authors
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
Affiliations
  • St. Jude Children's Research Hospital (US)
  • German Cancer Research Center (DE)
  • Hospital for Sick Children (CA)
  • University of Copenhagen (DK)
  • Massachusetts Institute of Technology (US)
  • European Molecular Biology Laboratory (DE)
  • Max Planck Institute for Molecular Genetics (DE)
  • Broad Institute (US)
  • Burdenko Neurosurgery Institute (RU)
  • Oregon Health & Science University (US)
  • Boston Children's Hospital (US)
  • Universitätsklinikum Tübingen (DE)
  • University Children's Hospital Tübingen (DE)
  • University of California, Los Angeles (US)
  • Hospital Sant Joan de Déu Barcelona (ES)
  • Duke University (US)
  • McGill University (CA)
  • Kitasato University Hospital (JP)
  • BC Cancer Agency (CA)
  • University Hospital Heidelberg (DE)
Corresponding author
  • Pfister, Stefan M.
  • Taylor, Michael D.
  • Lichter, Peter
Venue
Nature
Published
2017-07
Volume
547
Issue
7663
Pages
311-317
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2737542366
Cited by
1,112
References
66
Citations by year
2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
FWCI
54.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Max Planck Digital Library (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
  • OPUS (Augsburg University) (submittedVersion, cc-by)
Funders
  • Alexander and Margaret Stewart Trust
  • Pediatric Brain Tumor Foundation (R01CA159859)
  • Deutsches Krebsforschungszentrum
  • Genome Canada (R01CA159859)
  • Children's Hospital Foundation
  • Ontario Institute for Cancer Research
  • American Lebanese Syrian Associated Charities
  • Government of Ontario
  • Genome British Columbia (R01CA159859)
  • Canada Research Chairs
  • Brain Tumour Charity (GN-000356)
  • Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
  • Terry Fox Research Institute (R01CA159859)
  • Deutsche Krebshilfe (109252)
  • Hospital for Sick Children
  • Stichting Kinderen Kankervrij
  • BC Cancer Foundation (FDN-143288)
  • Brain Tumour Research
  • National Institutes of Health
  • Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
  • Garron Family Cancer Centre
  • National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
MeSH terms
Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The whole-genome landscape of medulloblastoma subtypes. https://app.cochat.ai/papers/10.1038/nature22973
The paper
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., . . . Lichter, P. (2017). The whole-genome landscape of medulloblastoma subtypes. Nature. https://doi.org/10.1038/nature22973

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.